Cargando…

The Effect of Iron Deficiency on Cardiac Function and Structure in Heart Failure with Reduced Ejection Fraction

Over the past decade, the detrimental impact of iron deficiency in heart failure with reduced ejection fraction has become abundantly clear, showing a negative impact on functional status, quality of life, cardiac function and structure, exercise capacity and an increased risk of hospitalisation due...

Descripción completa

Detalles Bibliográficos
Autor principal:	Martens, Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Radcliffe Cardiology 2022
Materias:	Comorbidities
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977990/ https://www.ncbi.nlm.nih.gov/pubmed/35399547 http://dx.doi.org/10.15420/cfr.2021.26

Ejemplares similares

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES
por: Yeoh, Su E., et al.
Publicado: (2021)

Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2013)

Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study
por: Alnuwaysir, Ridha I.S., et al.
Publicado: (2021)

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
por: Adamson, Carly, et al.
Publicado: (2021)

Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2022)

Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021)

The Impact of Frailty and Comorbidities on Heart Failure Outcomes
por: Salmon, Thomas, et al.
Publicado: (2022)

Urinary peptides in heart failure: a link to molecular pathophysiology
por: He, Tianlin, et al.
Publicado: (2021)

Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence
por: Janse, Roemer J., et al.
Publicado: (2022)

Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF
por: McEwan, Phil, et al.
Publicado: (2021)

The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis
por: van den Oever, I. A. M., et al.
Publicado: (2020)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
por: Rosenkranz, Stephan, et al.
Publicado: (2021)

Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late Life
por: Vu, Katja, et al.
Publicado: (2021)

Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies
por: Mugii, Naoki, et al.
Publicado: (2018)

Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity
por: Biskup, Małgorzata, et al.
Publicado: (2018)

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017
por: Lindner, Lisa, et al.
Publicado: (2020)

Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome
por: Traianos, Emmanuella Young, et al.
Publicado: (2020)

Self-reported fatigue in patients with rheumatoid arthritis compared to patients with cancer: results from two large-scale studies
por: Müller, Karolina, et al.
Publicado: (2021)

The association between type 2 diabetes and anhedonic subtype of major depression in hypertensive individuals
por: Willame, Hadrien, et al.
Publicado: (2022)

Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications
por: Kloner, Robert A., et al.
Publicado: (2022)

Tadalafil in patients on antihypertensive medications: Does safety remain an issue?
por: Theofilis, Panagiotis, et al.
Publicado: (2022)

The role of tadalafil in treated hypertensive patients with erectile dysfunction
por: Grossman, Ehud
Publicado: (2022)

Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014–2017
por: Weisshaar, Stefan, et al.
Publicado: (2022)

Evolution of tricuspid regurgitation after transcatheter edge‐to‐edge mitral valve repair for secondary mitral regurgitation and its impact on mortality
por: Adamo, Marianna, et al.
Publicado: (2022)

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)

The Role of Cardiac Imaging in Heart Failure with Reduced Ejection Fraction
por: Gosling, Rebecca C, et al.
Publicado: (2022)

Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction
por: Alcaide-Aldeano, Alex, et al.
Publicado: (2020)

Association of Depression and Anxiety with Cardiac Structural and Functional Characteristics in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
por: Szabo, Timea Magdolna, et al.
Publicado: (2023)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation
por: Zaccone, Gregorio, et al.
Publicado: (2021)

Scoring Systems to Predict Survival or Neurological Recovery after Out-of-hospital Cardiac Arrest
por: Naik, Rishi, et al.
Publicado: (2022)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Management of heart failure with reduced ejection fraction
por: Haydock, Paul M, et al.
Publicado: (2022)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Factors Related to Maternal Adverse Outcomes in Pregnant Women with Cardiac Disease in Low-resource Settings
por: Poli, Philippe Amubuomombe, et al.
Publicado: (2020)

Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Beale, Anna L, et al.
Publicado: (2019)

Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction
por: Barandiarán Aizpurua, Arantxa, et al.
Publicado: (2021)

Iron therapy in iron-deficiency patients with heart failure with preserved ejection fraction: A protocol for meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g1i73onjrhn0ntifc76th3lk97